ArticleResearch square2026
Successful Ocular Structural Restoration of Aggressive Necrotizing Sclerouveitis Following Pterygium Excision: Infectious, Autoimmune, or Both?
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Purpose: To report a case of severe refractory surgically induced scleral necrosis (SISN) with pan-uveitis and retinal detachment following pterygium excision, highlighting the challenges in differentiating infectious versus autoimmune mechanisms and demonstrating successful restoration of ocular structure with combined surgical and immunosuppressive therapy in a patient with poor initial prognosis. Observation: An 80-year-old man presented one year after pterygium surgery with severe pain, redness, and vision loss in the right eye. Examination revealed nasal necrotizing scleritis with purulent discharge, extensive scleral thinning and uveal exposure, pan-uveitis, serous retinal detachment, and choroidal folds. Co-infection was suspected, and systemic autoimmune predisposition was suggested by p-ANCA positivity and history of cutaneous lupus. The patient underwent urgent scleral debridement and biopsy, along with topical and systemic antibiotics, followed by weekly rituximab infusions and mycophenolate mofetil under steroid taper. After eight cycles of active treatment, scleral inflammation improved significantly, scleral thickness restored, and retinal detachment and subretinal fluid completely resolved. At last follow-up, visual acuity improved from counting fingers to 20/100 with restoration of ocular structural integrity. Conclusion: The index case highlights the challenge of distinguishing infection from autoimmunity in SISN. Early debridement, prompt antimicrobial treatment, and immunosuppressive therapy are crucial in the management of SISN. Rituximab infusion is safe and effective for rapidly controlling severe scleral inflammation once infection is ruled out or is under control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.